(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)
`(19) World Intellectual Property
`Organization
`International Bureau
`
`(10) International Publication Number
`
`WO 2014/182970 A1
`
`\&
`
`WIPOI PCT
`
`(43) International Publication Date
`13 November 2014 (13.11.2014)
`
`(51)
`
`International Patent Classification:
`A61K 39/395 (2006.01)
`
`(21)
`
`International Application Number:
`
`(22)
`
`International Filing Date:
`
`PCT/US2014/037401
`
`(25)
`
`(26)
`
`(30)
`
`(71)
`
`(72)
`(71)
`
`Filing Language:
`
`Publication Language:
`
`8 May 2014 (08.05.2014)
`
`English
`
`English
`
`Priority Data:
`61/821,197
`
`8 May 2013 (08.05.2013)
`
`US
`
`Applicant for all designated States except US): ZY-
`MEWORKS INC. [CA/CA]; 540-1385 West 8th Avenue,
`Vancouver, British Columbia, V6H 3 V9 (CA).
`
`Inventor; and
`Applicant
`(for US only): NG, Gordon, Yiu Kon
`[US/CA]; C/o Zymeworks Inc., 540-1385 West 8th Aven-
`ue, Vancouver, British Columbia, V6H 3 V9 (CA).
`
`(72)
`
`(74)
`
`(81)
`
`Inventors: CHAN, Peter, Wing Yiu; C/o Zyrneworks
`Inc., 540-1385 West 8th Avenue, Vancouver, British
`Columbia, V6H 3 V9 (CA). WICKMAN, Grant, Ray-
`mond; C/o Zymeworks Inc., 540-1385 West 8th Avenue,
`Vancouver, British Columbia, V6H 3 V9 (CA).
`
`Agents: HUBL, Susan, '1'. et a1.; Fenwick & West LLP,
`801 California Street, Mountain View, CA 94041 (US).
`
`Designated States (unless otherwise indicated, for every
`kind ofnational protection available): AE, AG, AL, AM,
`AO, AT, AU, AZ, BA, BB, BG, BH, RN, BR, BW, BY,
`BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
`DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
`HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
`KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
`MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
`OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
`SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
`TN, TR, TT, TZ, UA, UG, Us, UZ, vc, VN, ZA, ZM,
`ZW.
`
`(54) Title: BISPECIFIC HER2 AND HER3 ANTIGEN BINDING CONSTRUCTS
`
`[Continued on nextpagej
`
`(57) Abstract: Described herein are isolated bi-specific antigen binding
`constructs, e. g., antibodies. The bi-specific antigen binding constnicts in-
`clude two antigen binding polypeptide constructs, e. g., a Fab and an scFv.
`The first antigen-binding polypeptide construct monovalently and specific-
`ally binds to extracellular domain 4 (ECD4) of HER2 (human epidermal
`growth factor receptor 2);
`the second antigen-binding polypeptide cori-
`struct monovalently and specifically binds to an extracellular domain
`(ECD) of HER3 (human epidermal growth factor receptor 3). One antigen
`binding polypeptide construct is a Fab format and the other antigen bind—
`ing polypeptide construct is an scFv format. The bi- specific antigen bind-
`ing constructs includes an Fc having two Fc polypeptides each having a
`CH3 domain for dimerization. Each Fc polypeptide is linked to the C-ter-
`minus of one of the antigen binding polypeptide constructs with or without
`a linker.
`
`V506
`
`
`
`
`FIG. 33
`
`
`
`W02014/182970A1|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
`
`